CISPLATIN injection, USP – prescribing information (boxed warning: nephrotoxicity, peripheral neuropathy, nausea and vomiting, myelosuppression) (2023)

Government Record · Accord Healthcare Inc. (label); U.S. Food and Drug Administration (approval) · December 2023

Accord Healthcare Inc. (label), 2023-12: The cisplatin label's boxed warning makes nephrotoxicity the first listed danger, describing dose-related, cumulative severe renal toxicity including acute renal failure.

Nephrotoxicity: cisplatin injection can cause severe renal toxicity, including acute renal failure. Severe renal toxicities are dose-related and cumulative.

PDF p.3 (boxed warning)

Accord Healthcare Inc. (label), 2023-12: The cisplatin label's boxed warning makes nephrotoxicity the first listed danger, describing dose-related, cumulative severe renal toxicity including acute renal failure. Regulatory text: no funder/COI; maker Accord (generic), initial U.S. approval 1978. No percentage for nephrotoxicity appears in the label; it gives 25% to 30% for myelosuppression and 40-60% hearing-loss prevalence in paediatric patients. The 30% kidney figure must come from cohort data (see CHB-25). Study type: regulatory record.